Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial

Clinical trial NCT06591273 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06591273
Sponsor: Services Institute of Medical Sciences, Pakistan
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Moderate to Severe Chronic Plaque Psoriasis

Start date: 2023-11-06
Primary completion: 2024-11-05
Enrollment: 104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.